Pub Date : 2026-01-23DOI: 10.1016/j.cellsig.2026.112390
Rong Fu , Lei Shi
Parkinson's Disease (PD) is a common neurodegenerative disorder with a complex and incompletely elucidated pathogenesis. Dysregulated immunity plays a pivotal role in the initiation and progression of the disease. The cyclic guanosine monophosphate (GMP)- adenosine monophosphate (AMP) synthase (cGAS)-stimulator of interferon genes (STING) pathway, an intracellular innate immune signaling cascade that has attracted considerable attention in recent years, exerts crucial functions in sensing pathogen invasion and endogenous damage-associated molecular patterns (DAMPs), as well as regulating immune responses. This review thoroughly explores the role of the cGAS-STING pathway in PD immune regulation. It first details the pathway's structural components and activation mechanism, then analyzes its aberrant activation under PD pathological conditions. Furthermore, it discusses in detail the specific mechanisms underlying its role in PD immune regulation, including its impacts on microglial activation, inflammatory cytokine release, α-synuclein (α-syn) aggregation and clearance, as well as neuronal survival. Meanwhile, it summarizes the current research progress in targeting the cGAS-STING pathway for PD treatment. Finally, it points out the existing challenges and future research directions in this field, aiming to provide novel insights and theoretical foundations for investigating PD pathogenesis and developing clinical therapeutic strategies.
{"title":"Cross-talk between neuroinflammation and α-synuclein aggregation: The central role of the cGAS-STING pathway in Parkinson's disease","authors":"Rong Fu , Lei Shi","doi":"10.1016/j.cellsig.2026.112390","DOIUrl":"10.1016/j.cellsig.2026.112390","url":null,"abstract":"<div><div>Parkinson's Disease (PD) is a common neurodegenerative disorder with a complex and incompletely elucidated pathogenesis. Dysregulated immunity plays a pivotal role in the initiation and progression of the disease. The cyclic guanosine monophosphate (GMP)- adenosine monophosphate (AMP) synthase (cGAS)-stimulator of interferon genes (STING) pathway, an intracellular innate immune signaling cascade that has attracted considerable attention in recent years, exerts crucial functions in sensing pathogen invasion and endogenous damage-associated molecular patterns (DAMPs), as well as regulating immune responses. This review thoroughly explores the role of the cGAS-STING pathway in PD immune regulation. It first details the pathway's structural components and activation mechanism, then analyzes its aberrant activation under PD pathological conditions. Furthermore, it discusses in detail the specific mechanisms underlying its role in PD immune regulation, including its impacts on microglial activation, inflammatory cytokine release, α-synuclein (α-syn) aggregation and clearance, as well as neuronal survival. Meanwhile, it summarizes the current research progress in targeting the cGAS-STING pathway for PD treatment. Finally, it points out the existing challenges and future research directions in this field, aiming to provide novel insights and theoretical foundations for investigating PD pathogenesis and developing clinical therapeutic strategies.</div></div>","PeriodicalId":9902,"journal":{"name":"Cellular signalling","volume":"141 ","pages":"Article 112390"},"PeriodicalIF":3.7,"publicationDate":"2026-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146045967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Migrasomes, a recently identified class of organelles, form at the tips or intersections of retraction fibers during cell migration. These structures carry various bioactive cargoes, including proteins, mRNAs, and cytokines, and play significant roles in intercellular communication, immune regulation, and tissue homeostasis. As specialized membrane structures generated during cell migration, migrasomes are not only involved in physiological processes such as embryonic development and vascular homeostasis but are also critically implicated in the pathogenesis of neurological disorders. In this review, we outline the fundamental biological characteristics and functions of migrasomes, provide an in-depth analysis of their pathological mechanisms in neurological diseases, and evaluate their clinical potential as novel diagnostic biomarkers, drug delivery vehicles, and therapeutic targets. Overall, this review offers new perspectives for precision diagnostics and therapeutics of neurological diseases and lays a foundation for diagnosing and treating migrasome-related pathologies.
{"title":"Mechanisms and therapeutic potential of migrasomes in neurological disorders","authors":"Simeng Zhang, Yanhua Yang, Tiancheng Zhang, Ye Pan, Qinggang Xu, Peng Lü","doi":"10.1016/j.cellsig.2026.112389","DOIUrl":"10.1016/j.cellsig.2026.112389","url":null,"abstract":"<div><div>Migrasomes, a recently identified class of organelles, form at the tips or intersections of retraction fibers during cell migration. These structures carry various bioactive cargoes, including proteins, mRNAs, and cytokines, and play significant roles in intercellular communication, immune regulation, and tissue homeostasis. As specialized membrane structures generated during cell migration, migrasomes are not only involved in physiological processes such as embryonic development and vascular homeostasis but are also critically implicated in the pathogenesis of neurological disorders. In this review, we outline the fundamental biological characteristics and functions of migrasomes, provide an in-depth analysis of their pathological mechanisms in neurological diseases, and evaluate their clinical potential as novel diagnostic biomarkers, drug delivery vehicles, and therapeutic targets. Overall, this review offers new perspectives for precision diagnostics and therapeutics of neurological diseases and lays a foundation for diagnosing and treating migrasome-related pathologies.</div></div>","PeriodicalId":9902,"journal":{"name":"Cellular signalling","volume":"141 ","pages":"Article 112389"},"PeriodicalIF":3.7,"publicationDate":"2026-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146046028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-23DOI: 10.1016/j.cellsig.2026.112391
Arian Ansardamavandi , Mohammad Tafazzoli-Shadpour
The tumour microenvironment (TME) represents a complex, dynamic ecosystem comprising cellular and acellular elements that collectively facilitate tumour progression, invasion, and metastasis through intricate chemo-mechanical interactions. Cancer cells drive TME remodelling by recruiting and reprogramming stromal components, including cancer-associated fibroblasts (CAFs) that alter extracellular matrix (ECM) composition and stiffness, tumour-associated macrophages (TAMs) that promote immunosuppressive conditions, and tumour endothelial cells (TECs) that establish aberrant vascular networks. This review synthesises current literature on the pivotal role of TECs in tumour angiogenesis, emphasising their bidirectional crosstalk with cancer and stromal cells via chemical signals (e.g., growth factors under hypoxia) and mechanical cues (e.g., ECM stiffness and topography) that modulate cellular contractility, adhesion, and biochemical release. Key findings reveal how TECs integrate these multifaceted stimuli to orchestrate vascular remodelling, enhance permeability, and foster metastatic dissemination, often through dysregulated pathways distinct from normal endothelium. Ultimately, elucidating these mechanisms offers promising avenues for developing targeted therapies that selectively inhibit TEC-mediated angiogenesis while preserving physiological vascular function.
{"title":"Tumour endothelial cells in cancer: Chemo-physical crosstalk and angiogenic signalling in the tumour microenvironment","authors":"Arian Ansardamavandi , Mohammad Tafazzoli-Shadpour","doi":"10.1016/j.cellsig.2026.112391","DOIUrl":"10.1016/j.cellsig.2026.112391","url":null,"abstract":"<div><div>The tumour microenvironment (TME) represents a complex, dynamic ecosystem comprising cellular and acellular elements that collectively facilitate tumour progression, invasion, and metastasis through intricate chemo-mechanical interactions. Cancer cells drive TME remodelling by recruiting and reprogramming stromal components, including cancer-associated fibroblasts (CAFs) that alter extracellular matrix (ECM) composition and stiffness, tumour-associated macrophages (TAMs) that promote immunosuppressive conditions, and tumour endothelial cells (TECs) that establish aberrant vascular networks. This review synthesises current literature on the pivotal role of TECs in tumour angiogenesis, emphasising their bidirectional crosstalk with cancer and stromal cells via chemical signals (e.g., growth factors under hypoxia) and mechanical cues (e.g., ECM stiffness and topography) that modulate cellular contractility, adhesion, and biochemical release. Key findings reveal how TECs integrate these multifaceted stimuli to orchestrate vascular remodelling, enhance permeability, and foster metastatic dissemination, often through dysregulated pathways distinct from normal endothelium. Ultimately, elucidating these mechanisms offers promising avenues for developing targeted therapies that selectively inhibit TEC-mediated angiogenesis while preserving physiological vascular function.</div></div>","PeriodicalId":9902,"journal":{"name":"Cellular signalling","volume":"141 ","pages":"Article 112391"},"PeriodicalIF":3.7,"publicationDate":"2026-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146046018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-21DOI: 10.1016/j.cellsig.2026.112386
Xiaofeng Li , Yi Liu , Shiyu Sha , Haoling Li , Yingqiang Fu , Shenghou Liu , Qingfeng Yin , Xin Pan , Wenguang Liu
Osteoporosis is characterized by reduced bone mass and impaired skeletal microarchitecture, with impaired osteogenic differentiation capacity of bone marrow mesenchymal stem cells (BMSCs) serving as a key contributing factor in its development. Cellular repressor of E1A-stimulated genes 1 (CREG1), a lysosomal glycoprotein, has been implicated in the regulation of autophagy and osteogenic differentiation. However, the molecular mechanisms underlying CREG1-mediated bone homeostasis remain unclear. In this study, we identified RAB7, a small GTPase involved in endosomal trafficking and autophagy, as a downstream effector of CREG1. We found that RAB7 expression progressively increased during osteogenic differentiation of BMSCs. RAB7 knockdown impaired osteogenesis, whereas its overexpression enhanced the process. Functional assays demonstrated that modulation of RAB7 expression significantly influenced the effects of CREG1 on BMSCs. RAB7 knockdown inhibited CREG1-induced osteogenic differentiation and autophagy activation, whereas RAB7 overexpression restored the osteogenic potential suppressed by CREG1 knockdown. Our findings suggest that CREG1 facilitates osteogenic differentiation and bone homeostasis via RAB7-mediated regulation of autophagy.
{"title":"CREG1 promotes bone formation via targeting RAB7 to activate autophagy in osteoporosis","authors":"Xiaofeng Li , Yi Liu , Shiyu Sha , Haoling Li , Yingqiang Fu , Shenghou Liu , Qingfeng Yin , Xin Pan , Wenguang Liu","doi":"10.1016/j.cellsig.2026.112386","DOIUrl":"10.1016/j.cellsig.2026.112386","url":null,"abstract":"<div><div>Osteoporosis is characterized by reduced bone mass and impaired skeletal microarchitecture, with impaired osteogenic differentiation capacity of bone marrow mesenchymal stem cells (BMSCs) serving as a key contributing factor in its development. Cellular repressor of E1A-stimulated genes 1 (CREG1), a lysosomal glycoprotein, has been implicated in the regulation of autophagy and osteogenic differentiation. However, the molecular mechanisms underlying CREG1-mediated bone homeostasis remain unclear. In this study, we identified RAB7, a small GTPase involved in endosomal trafficking and autophagy, as a downstream effector of CREG1. We found that RAB7 expression progressively increased during osteogenic differentiation of BMSCs. RAB7 knockdown impaired osteogenesis, whereas its overexpression enhanced the process. Functional assays demonstrated that modulation of RAB7 expression significantly influenced the effects of CREG1 on BMSCs. RAB7 knockdown inhibited CREG1-induced osteogenic differentiation and autophagy activation, whereas RAB7 overexpression restored the osteogenic potential suppressed by CREG1 knockdown. Our findings suggest that CREG1 facilitates osteogenic differentiation and bone homeostasis <em>via</em> RAB7-mediated regulation of autophagy.</div></div>","PeriodicalId":9902,"journal":{"name":"Cellular signalling","volume":"141 ","pages":"Article 112386"},"PeriodicalIF":3.7,"publicationDate":"2026-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146040753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-20DOI: 10.1016/j.cellsig.2026.112385
Ning Qu , WenJie You , LingLi Gong , KaiYun Wang , Qi Shu , LuoLong Tao , YanLong Zhong , QiHua Qi , Wei Zuo
Spinal cord injury (SCI) is a global health issue which can lead to severe neurological impairment. NR4A1 is rapidly induced in response to diverse stimuli and shows multiple important functions in the central nervous system (CNS). However, its functional contribution to spinal cord injury remains undefined.
In this study, NR4A1 expression was significantly down-regulated in microglia of a mouse contusion SCI model, accompanied by increased expression of VAV1 and pro-inflammatory cytokines (TNF-α, IL-1β, IL-6). Treating with cytosporone B (CsnB) can decrease VAV1 expression, reduced inflammatory response, reduced injury area, and improved locomotor function of SCI mice. Further analysis indicated that Csn-B promoted microglial polarization from M1 to M2 phenotype, with decrease of TNF-α, IL-1β and IL-6expression. Conversely, administration of DIM-C-pPhOH (C-DIM8) produced completely opposite results. In vitro, an inflammatory model that mimics SCI in vivo was established by stimulating BV2 microglial cells with LPS (200 ng/ml, 24 h). Further mechanistic investigation revealed that NR4A1 over-expression active BV2 cells from M1 to M2 phenotype and suppressed TNF-α, IL-1β and IL-6 release. NR4A1 knockdown, in contrast, promoted BV2 from M2 to M1 phenotype and enhanced TNF-α, IL-1β and IL-6 release. Further studies identified that NR4A1 functions as a direct transcriptional repressor of VAV1. Knockdown/over-express VAV1 could reverse the effects of NR4A1 knockdown/over-express on LPS-stimulated BV2 cells, respectively.
Collectively, this study demonstrates that NR4A1 alleviates SCI-induced neuroinflammation by modulating microglial polarization via negatively regulating the VAV1 signaling pathway. Targeting the NR4A1-VAV1 axis may be a promising therapeutic target for mitigating SCI progression.
{"title":"NR4A1 attenuates neuroinflammation after spinal cord injury by modulating microglial polarization via negatively regulating the VAV1 pathway","authors":"Ning Qu , WenJie You , LingLi Gong , KaiYun Wang , Qi Shu , LuoLong Tao , YanLong Zhong , QiHua Qi , Wei Zuo","doi":"10.1016/j.cellsig.2026.112385","DOIUrl":"10.1016/j.cellsig.2026.112385","url":null,"abstract":"<div><div>Spinal cord injury (SCI) is a global health issue which can lead to severe neurological impairment. NR4A1 is rapidly induced in response to diverse stimuli and shows multiple important functions in the central nervous system (CNS). However, its functional contribution to spinal cord injury remains undefined.</div><div>In this study, NR4A1 expression was significantly down-regulated in microglia of a mouse contusion SCI model, accompanied by increased expression of VAV1 and pro-inflammatory cytokines (TNF-α, IL-1β, IL-6). Treating with cytosporone B (Csn<img>B) can decrease VAV1 expression, reduced inflammatory response, reduced injury area, and improved locomotor function of SCI mice. Further analysis indicated that Csn-B promoted microglial polarization from M1 to M2 phenotype, with decrease of TNF-α, IL-1β and IL-6expression. Conversely, administration of DIM-C-pPhOH (C-DIM8) produced completely opposite results. In vitro, an inflammatory model that mimics SCI in vivo was established by stimulating BV2 microglial cells with LPS (200 ng/ml, 24 h). Further mechanistic investigation revealed that NR4A1 over-expression active BV2 cells from M1 to M2 phenotype and suppressed TNF-α, IL-1β and IL-6 release. NR4A1 knockdown, in contrast, promoted BV2 from M2 to M1 phenotype and enhanced TNF-α, IL-1β and IL-6 release. Further studies identified that NR4A1 functions as a direct transcriptional repressor of VAV1. Knockdown/over-express VAV1 could reverse the effects of NR4A1 knockdown/over-express on LPS-stimulated BV2 cells, respectively.</div><div>Collectively, this study demonstrates that NR4A1 alleviates SCI-induced neuroinflammation by modulating microglial polarization via negatively regulating the VAV1 signaling pathway. Targeting the NR4A1-VAV1 axis may be a promising therapeutic target for mitigating SCI progression.</div></div>","PeriodicalId":9902,"journal":{"name":"Cellular signalling","volume":"141 ","pages":"Article 112385"},"PeriodicalIF":3.7,"publicationDate":"2026-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146028431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-19DOI: 10.1016/j.cellsig.2026.112384
Wenyu Zang , Wenshuai Zhu , Fubo Jing , He Qi , Xiaoli Ma , Yunshan Wang , Yanfei Jia
The Hh signaling pathway critically drives tumorigenesis and progression in multiple cancers, including gastrointestinal cancers such as gastric, hepatic, pancreatic, esophageal, and colorectal cancer. Aberrant Hh signaling pathway activation, often driven by ligands such as Sonic Hedgehog (Shh) and transcription factors such as Gli1/2, promotes tumor cell proliferation, survival, metastasis, cancer stem cells, and chemoresistance while inhibiting programmed cell death pathways. High levels of Hh signaling pathway activity are a characteristic feature of gastrointestinal cancers. Therapeutic targeting of the Hh signaling pathway has shown promise, with Smoothened (Smo) inhibitors approved for basal cell carcinoma but yielding mixed results in gastrointestinal cancer trials. Emerging strategies, including Hh inhibitors; natural compounds from traditional Chinese medicine; and combinations of chemotherapy, immunotherapy or radiation to induce cell death and remodel the tumor microenvironment, could lead to a new therapeutic avenue for gastrointestinal cancers. In this review, we summarize advances in our understanding of Hh-mediated cell death in gastrointestinal cancers and the role and mechanisms, and highlight the underlying therapeutic opportunities. These new findings advance the rapidly expanding field of translational cancer research focused on the Hh signaling pathway.
{"title":"The role of the hedgehog signaling pathway in the regulation of gastrointestinal cancer cell death","authors":"Wenyu Zang , Wenshuai Zhu , Fubo Jing , He Qi , Xiaoli Ma , Yunshan Wang , Yanfei Jia","doi":"10.1016/j.cellsig.2026.112384","DOIUrl":"10.1016/j.cellsig.2026.112384","url":null,"abstract":"<div><div>The Hh signaling pathway critically drives tumorigenesis and progression in multiple cancers, including gastrointestinal cancers such as gastric, hepatic, pancreatic, esophageal, and colorectal cancer. Aberrant Hh signaling pathway activation, often driven by ligands such as Sonic Hedgehog (Shh) and transcription factors such as Gli1/2, promotes tumor cell proliferation, survival, metastasis, cancer stem cells, and chemoresistance while inhibiting programmed cell death pathways. High levels of Hh signaling pathway activity are a characteristic feature of gastrointestinal cancers. Therapeutic targeting of the Hh signaling pathway has shown promise, with Smoothened (Smo) inhibitors approved for basal cell carcinoma but yielding mixed results in gastrointestinal cancer trials. Emerging strategies, including Hh inhibitors; natural compounds from traditional Chinese medicine; and combinations of chemotherapy, immunotherapy or radiation to induce cell death and remodel the tumor microenvironment, could lead to a new therapeutic avenue for gastrointestinal cancers. In this review, we summarize advances in our understanding of Hh-mediated cell death in gastrointestinal cancers and the role and mechanisms, and highlight the underlying therapeutic opportunities. These new findings advance the rapidly expanding field of translational cancer research focused on the Hh signaling pathway.</div></div>","PeriodicalId":9902,"journal":{"name":"Cellular signalling","volume":"141 ","pages":"Article 112384"},"PeriodicalIF":3.7,"publicationDate":"2026-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146017420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-17DOI: 10.1016/j.cellsig.2026.112369
Tao Ran , Qing-xiu Zhang , Hua-yue Wu , Shu Feng , Lu Han , Yuan Qin , Guo-yuan Lin , Ya Zhang , Shi-liang Li , Ji-yu Chen , Yu-mei Zhou , Shi-qian Cai , Xue-ke Zhao
Liver fibrosis (LF) represents a common wound-healing response to various forms of liver injury. Activation of hepatic stellate cells (HSCs) is a central event in this process. Aerobic glycolysis plays a critical role in the sustained activation of HSCs. Human aldo-keto reductase family 1 member C3 (AKR1C3), a multifunctional enzyme, is upregulated in many diseases and has been identified as a drug target in cancer treatment. However, the underlying mechanism through which AKR1C3 is involved in LF remains unclear. This study indicated the elevated expression of AKR1C3 in the fibrotic tissues of both humans and rats. AKR1C3 overexpression stimulated the proliferation, migration, and activation of HSCs in vitro. These effects were reversed by inhibiting AKR1C3. Based on RNA-seq analysis, we investigated the underlying mechanism of AKR1C3 and found that glycolysis and the AKT/mTOR pathway may contribute to the effect of AKR1C3 on LF. Mechanistically, AKR1C3 may act as a molecular scaffold to mediate the binding of mTORC2 to AKT, thereby promoting the phosphorylation of AKT at Ser473 and activating the signaling pathway. In addition, AKR1C3 overexpression promoted aerobic glycolysis in HSCs by activating the AKT/mTOR pathway, but these effects were partly reversed by glycolysis inhibitors (2-DG) and AKT inhibitors (MK-2206). Our findings revealed the mechanism by which AKR1C3 promotes LF, suggesting that AKR1C3 may serve as a potential therapeutic target for LF, warranting further studies.
{"title":"AKR1C3 promotes aerobic glycolysis in hepatic stellate cells via the AKT/mTOR pathway to induce liver fibrosis","authors":"Tao Ran , Qing-xiu Zhang , Hua-yue Wu , Shu Feng , Lu Han , Yuan Qin , Guo-yuan Lin , Ya Zhang , Shi-liang Li , Ji-yu Chen , Yu-mei Zhou , Shi-qian Cai , Xue-ke Zhao","doi":"10.1016/j.cellsig.2026.112369","DOIUrl":"10.1016/j.cellsig.2026.112369","url":null,"abstract":"<div><div>Liver fibrosis (LF) represents a common wound-healing response to various forms of liver injury. Activation of hepatic stellate cells (HSCs) is a central event in this process. Aerobic glycolysis plays a critical role in the sustained activation of HSCs. Human aldo-keto reductase family 1 member C3 (AKR1C3), a multifunctional enzyme, is upregulated in many diseases and has been identified as a drug target in cancer treatment. However, the underlying mechanism through which AKR1C3 is involved in LF remains unclear. This study indicated the elevated expression of AKR1C3 in the fibrotic tissues of both humans and rats. AKR1C3 overexpression stimulated the proliferation, migration, and activation of HSCs in vitro. These effects were reversed by inhibiting AKR1C3. Based on RNA-seq analysis, we investigated the underlying mechanism of AKR1C3 and found that glycolysis and the AKT/mTOR pathway may contribute to the effect of AKR1C3 on LF. Mechanistically, AKR1C3 may act as a molecular scaffold to mediate the binding of mTORC2 to AKT, thereby promoting the phosphorylation of AKT at Ser473 and activating the signaling pathway. In addition, AKR1C3 overexpression promoted aerobic glycolysis in HSCs by activating the AKT/mTOR pathway, but these effects were partly reversed by glycolysis inhibitors (2-DG) and AKT inhibitors (MK-2206). Our findings revealed the mechanism by which AKR1C3 promotes LF, suggesting that AKR1C3 may serve as a potential therapeutic target for LF, warranting further studies.</div></div>","PeriodicalId":9902,"journal":{"name":"Cellular signalling","volume":"141 ","pages":"Article 112369"},"PeriodicalIF":3.7,"publicationDate":"2026-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146003187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-16DOI: 10.1016/j.cellsig.2026.112367
Gustavo A. Sosa, Betsy Crosswhite, Austin N. Kirschner
{"title":"Cellular signaling and radioresistance in prostate cancer","authors":"Gustavo A. Sosa, Betsy Crosswhite, Austin N. Kirschner","doi":"10.1016/j.cellsig.2026.112367","DOIUrl":"10.1016/j.cellsig.2026.112367","url":null,"abstract":"","PeriodicalId":9902,"journal":{"name":"Cellular signalling","volume":"141 ","pages":"Article 112367"},"PeriodicalIF":3.7,"publicationDate":"2026-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145997430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}